Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
Shunji TakahashiMasato KarayamaMasato TakahashiJunichiro WatanabeHironobu MinamiNoboru YamamotoIchiro KinoshitaChia-Chi LinYoung-Hyuck ImIssei AchiwaEmi KamiyamaYasuyuki OkudaCaleb LeeYung-Jue BangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
T-DXd was safely combined with ritonavir or itraconazole without clinically meaningful impact on T-DXd or DXd pharmacokinetics.